Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


4th Global Summit on Healthcare

Dubai, UAE

Kinda Khalaf

Khalifa University of Science, Technology and Research, UAE

Title: Engineering personalized medicine in the United Arab Emirates: Diabetes type 2 from diagnosis to therapy


Biography: Kinda Khalaf


At a prevalence rate close to 25%, the UAE has one of the highest rates of type 2 diabetes (T2D) in the world, instigating huge societal costs, not only in terms of morbidity and mortality, but also in lost productivity and an immense burden on the healthcare system. Diabetic neuropathy, the main complication of diabetes, affects the heart, kidney and peripheral nerves and significantly increases the risk of heart attack, kidney failure and amputation, resulting in both significant life and limb loss. Pharmacological treatment is the preferred treatment for diabetes and associated complications. However, the effectiveness of existing medication is controversial and requires a better understanding of the genetic, metabolic and physiological basis of diabetes, as well as the diabetic neuropathy to improve drug delivery and treatment outcomes. Currently, there is no unified model of diabetic neuropathy based on identified genes specific to the Emirati population, which not only leads to an increased risk of diabetes and associated neuropathy but also influences treatment effectiveness. Microbubble drug delivery systems, currently under development, promise to provide better-individualized drug delivery to specific organs and hence better treatment outcomes. In line with the Abu Dhabi 2030 plan and Khalifa University mission of research and community service excellence, our project aims to combine new technologies for identifying target-disease associations starting with the genetic basis and finalizing with enhanced drug delivery and drug candidates by applying genetic-metabolic modelling and data mining to gain a better understanding of the pathophysiology involved in diabetic neuropathy. Our underlying goal is to develop a holistic UAE population-specific model of the disease process along with better drug delivery system that targets specific organs to enhance individualized preventative health care in the UAE.